Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells - Wikidata - awgldk - TriplyDB

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

http://www.wikidata.org/entity/Q28477427

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Successes and Challenges of PARP Inhibitors in Cancer Therapy Saturation diving alters folate status and biomarkers of DNA damage and repair Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.Role of PARP inhibitors in cancer biology and therapy Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.Quantification of cellular poly(ADP-ribosyl)ation by stable isotope dilution mass spectrometry reveals tissue- and drug-dependent stress response dynamics Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Lessons learned from radiation oncology clinical trials.Radiation therapy induces the DNA damage response in peripheral blood.Molecular pathways: targeting PARP in cancer treatment.A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.NOD-scid IL2R γnull mice engrafted with human peripheral blood mononuclear cells as a model to test therapeutics targeting human signaling pathways.PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

P2860

Q21129302-9BB10425-EEC1-4052-8A0E-A52AD95EBBB8 Q26777131-F695A4D6-F942-4CF2-9A1B-5A97D775867E Q28480543-21FA9860-E479-4BB9-A01D-48A9B191BADC Q33162197-57A27AF6-9410-45B9-84E6-8E8148073894 Q33415790-4131556C-F03A-4495-AB32-C64E5D15CC29 Q33897223-F0175757-89C9-4161-B893-5355D4C9E0DE Q34017010-D0FC7E93-688F-48C7-93E0-6EA102E4FFB9 Q34309488-4B3AA38B-6813-47E0-A706-4F121D995D83 Q35251489-E9944465-E3AB-46D8-879F-D6C3BCB9101E Q35745041-1F47FA57-988F-497B-86CA-60413942060B Q35869645-9405381B-2E32-49BF-9C42-7FDF9099F7F0 Q36171193-5BA5AD8D-275D-422E-8CCE-4FD8DD27C4F9 Q36270038-9D3390DD-E58E-4831-8EC5-2A36EEE48E94 Q36907188-CEF85246-0922-4A6F-9B03-BE68589EEE36 Q37227952-0C2A4776-7ACF-4858-B0AD-37F20D930F56 Q37623863-4AF27684-7503-4140-8445-73ABA58D442B Q37662359-2F4D2F6B-999D-438C-B532-35471DC99B69 Q39117815-F40CAD15-7EC2-4A5A-BE47-28AD05821608 Q39497723-CDC21CF2-7453-430D-B431-7801F0A9317E Q39510346-C012F90F-D59D-4161-91F5-BADCF7AC6CD2 Q41768955-DBE23B7F-31A1-462F-B821-AE60706DB091 Q42517340-6D56E00F-4BDC-42C8-A02F-324EDB3B2A3A Q53043418-0ACCFE23-8FD4-42E3-A28A-750C3CC75EFC

P2860

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

http://www.wikidata.org/entity/Q28477427

description

2011 nî lūn-bûn

@nan

2011 թուականին հրատարակուած գիտական յօդուած

@hyw

2011 թվականին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@ast

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@en

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@nl

type

label

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@ast

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@en

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@nl

prefLabel

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@ast

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@en

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@nl

P1433

Q28477427-FCE56547-2C0D-48CA-B3AD-57F58CB62C5E

P1476

Q28477427-9DE6EACB-A2C9-432C-A726-8731E95F8B8F

P2093

Q28477427-7FA4F2E5-A1D8-4CBF-BFC5-05DAC499D168

Q28477427-8516437F-EB7C-463F-B4E3-509BECE3F2EE

Q28477427-9ABC0204-5F18-4F36-B20C-79D66311C38A

Q28477427-9C629D1C-1CDE-4EAC-BCA0-CD8F6158B49C

Q28477427-E33EE8DE-D1F7-4971-84C0-3530B2B7851D

Q28477427-E6AA6E16-A46C-4E20-8626-EBE91E8B809C

Q28477427-EA0A0590-4249-4588-B4B1-AF5D835EDA0C

Q28477427-EC24E710-758C-428B-B371-50BC46CBA905

P2860

Q28477427-12583120-4501-4A48-B9E6-7EDFED4E48D6

Q28477427-12CAC249-4C96-46AD-955C-909D0DB87648

Q28477427-199C9D2B-3014-4302-A629-FC2F472BF9D9

Q28477427-1AF6E0A0-68E6-4373-ABFC-C25E9256EE57

Q28477427-211C2A24-E793-4A09-AC7F-EA67BC61D420

Q28477427-30031C63-8D53-4FBD-997C-475309926CF8

Q28477427-383663F0-6D4D-4A84-B39E-1E97BAB9B8B3

Q28477427-824D1B8B-DBB0-4AB5-98EB-68C1D6A29231

Q28477427-89B1A8C7-7505-4DF0-95C7-CFAA86017AD3

Q28477427-A0A90818-8F8A-4FC4-A48B-A21BB1B1036F

P304

Q28477427-72DBA9E4-B1C9-43A9-99B9-C1A9CCC31EA5

P31

Q28477427-5D7B3322-9E19-4E0D-88D2-0363E769AC6E

P356

Q28477427-778A97A2-09B2-459C-880E-47C1252738F2

P407

Q28477427-C65BC449-EC5C-4FA8-A1DE-645E8D393E94

P433

Q28477427-09762986-0B44-49D7-B4DF-125E4AC572FA

P478

Q28477427-CC75BE71-C14A-4F29-9D43-395287591C09

P577

Q28477427-BA480AE3-E687-4399-8A6A-151A66500159

P5875

Q28477427-D43EFDC1-4F17-44B2-8761-5E7EE01C51DD

P698

Q28477427-2209B3B7-21CC-478C-B2FA-165B09C8889D

P921

Q28477427-0AEFCAF5-B856-43B8-A216-36B3273B8F51

P932

Q28477427-1585E854-EA27-4EDC-94DD-BD40B56BCDAA

P356

JOURNAL.PONE.0026152

P1433

P1476

Modeling pharmacodynamic respo ...... pheral blood mononuclear cells

@en

P2093

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Jiuping Ji

http://www.w3.org/2001/XMLSchema#string

Joseph E Tomaszewski

http://www.w3.org/2001/XMLSchema#string

Larry Rubinstein

http://www.w3.org/2001/XMLSchema#string

Ralph E Parchment

http://www.w3.org/2001/XMLSchema#string

Robert J Kinders

http://www.w3.org/2001/XMLSchema#string

Shivaani Kummar

http://www.w3.org/2001/XMLSchema#string

Yiping Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.

The PARP superfamily.

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

PARP inhibitors for cancer therapy.

P304

e26152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0026152

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51746746

http://www.w3.org/2001/XMLSchema#string

P698

22028822

http://www.w3.org/2001/XMLSchema#string

P921

pharmacodynamics

P932

3189959

http://www.w3.org/2001/XMLSchema#string